Display Accessibility Tools

Accessibility Tools

Grayscale

Highlight Links

Change Contrast

Increase Text Size

Increase Letter Spacing

Dyslexia Friendly Font

Increase Cursor Size

Patents

  1. US21 45448 Proteasome enhancers and uses thereof. August 10, 2021
  2. US21 45446 Proteasome enhancers and uses thereof. August 10, 2021
  3. US21 45440 Proteasome enhancers and uses thereof. August 10, 2021
  4. US 2018-62623861A1 Pipecolic esters for inhibition of the proteasome, Jan. 30, 2019
  5. US2018/035869S mall molecule Proteasome Activators and uses thereof, Dec. 13, 2018
  6. US 2018/0282280A1 Quinoline-based proteasome inhibitors and uses thereof, Oct. 4, 2018.
  7. US 62/539,049. Treatment of malignancies. July 31, 2018
  8. US 62/515,403. Enhancement of proteasome activity for the treatment of neurodegenerative diseases. June 5, 2018
  9. US Provisional patent 62/479,805. Quinoline-based proteasome inhibitors. March 31, 2017
  10. US 8,552,206 B2. and European Patent: 03731545.4. NF-kB inhibitors and uses thereof. Oct. 8, 2013
  11. US 8,252,942 B2. Substituted imidazoline compounds. Aug. 12, 2012
  12. US 7,193,079 B1. Preparation of hymendialdisine derivates and use thereof. March 20, 2007
  13. US 6,878,735 B2. Multi-substituted imidazolines and method of use thereof. April 12, 2005